Table 1. Characteristics of 118 participants in a study of Streptococcus mitis strains causing severe clinical disease in patients with cancer*.
| Characteristic | No. (%) |
|---|---|
| Sex | |
| M | 64 (54) |
| F |
54 (46) |
| Mean age, y (SD, range) |
50 (18, 10–79) |
| Malignancy | 70 (59) |
| Leukemia/myelodysplastic syndrome | 20 (17) |
| Hematopoietic stem cell transplantation | 10 (8) |
| Lymphoma/myeloma | 18 (15) |
| Solid tumor |
20 (17) |
| Neutrophils <500/μL |
95 (81) |
| Clinical syndrome | |
| Primary bacteremia | 95 (80) |
| Gastrointestinal focus | 8 (7) |
| Skin/soft tissue focus | 4 (3) |
| Infective endocarditis | 2 (2) |
| Clinically minor bacteremia |
9 (7) |
| Polymicrobial infection |
22 (19) |
| Pitt bacteremia score†‡ | |
| 0 | 35 (37) |
| 1 | 36 (38) |
| 2 | 5 (5) |
| 3 | 7 (7) |
|
>4 |
13 (13) |
| Antimicrobial drug susceptibility | |
| Penicillin | 54 (46) |
| Ceftriaxone | 107 (91) |
| Moxifloxacin | 60 (51) |
| Tetracycline | 69 (59) |
*All patients had viridans group streptococci bacteremia. Unless otherwise noted, data are no. (%) of patients. †Severity of infection was measured by the Pitt bacteremia score as described (21). Scores of 0 or 1 indicate clinically mild infections; scores of >2 indicate moderate to severe infections. ‡Determined only for patients with monomicrobial infection.